Randomized phase II study of adjuvant sunitinib or valproic acid in high-risk patients with uveal melanoma: The final analysis of cohort 1.

被引：0
作者：
Seedor, Rino S.
Orloff, Marlana M.
Sharpe-Mills, Erin
Hulse, Liam
Shelat, Reshma
Shimada, Ayako
Chervoneva, Inna
Shields, Carol L.
Shields, Jerry A.
Mastrangelo, Michael J.
Sato, Takami
机构：
[1] Thomas Jefferson Univ, Sidney Kimmel Med Coll, Philadelphia, PA 19107 USA
[2] Wills Eye Hosp & Res Inst, Oncol Serv, Philadelphia, PA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
9586
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Adjuvant imatinib for patients with high-risk gastrointestinal stromal tumors: a retrospective cohort study
    Rui Zhao
    Yong Wang
    Yuqian Huang
    Yaping Cui
    Lin Xia
    Yi Chen
    Wen Zhuang
    Yong Zhou
    Xiaoting Wu
    Scientific Reports, 7
  • [32] Cost-effectiveness analysis of interferon as adjuvant therapy in high-risk melanoma patients in Spain
    González-Larriba, JL
    Serrano, S
    Alvarez-Mon, M
    Camacho, F
    Casado, MA
    Díaz-Pérez, JL
    Díaz-Rubio, E
    Fosbrook, L
    Guillem, V
    López-López, JJ
    Moreno-Nogueira, JA
    Toribio, J
    EUROPEAN JOURNAL OF CANCER, 2000, 36 (18) : 2344 - 2352
  • [33] Adjuvant imatinib for patients with high-risk gastrointestinal stromal tumors: a retrospective cohort study
    Zhao, Rui
    Wang, Yong
    Huang, Yuqian
    Cui, Yaping
    Xia, Lin
    Chen, Yi
    Zhuang, Wen
    Zhou, Yong
    Wu, Xiaoting
    SCIENTIFIC REPORTS, 2017, 7
  • [34] Study supports possible use of sargramostim as a potential adjuvant therapy for high-risk melanoma patients
    不详
    ONCOLOGY-NEW YORK, 2008, 22 (08): : 956 - 956
  • [35] Phase II single-arm multicenter study of adjuvant ipilimumab in combination with nivolumab in subjects with high-risk ocular melanoma.
    Rapisuwon, Suthee
    Patel, Sapna Pradyuman
    Carvajal, Richard D.
    Hernandez-Aya, Leonel Fernando
    Tsai, Katy K.
    Chandra, Sunandana
    Tan, Ming Tony
    Daud, Adil
    Sosman, Jeffrey Alan
    Atkins, Michael B.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [36] SPARC expression in patients with high-risk localized soft tissue sarcoma treated on a randomized phase II trial of neo/adjuvant chemotherapy
    Davis, Elizabeth J.
    Zhao, Lili
    Lucas, David R.
    Schuetze, Scott M.
    Baker, Laurence H.
    Zalupski, Mark M.
    Thomas, Dafydd
    Chugh, Rashmi
    BMC CANCER, 2016, 16
  • [37] Phase III trial of adjuvant sunitinib in patients with high-risk renal cell carcinoma: Comprehensive tumour genomic and transcriptomic analyses
    Ravaud, A.
    Martini, J-F.
    Ching, K.
    Staehler, M.
    Magheli, A.
    Escudier, B.
    Mu, X. J.
    Valota, O.
    Lin, X.
    Motzer, R. J.
    ANNALS OF ONCOLOGY, 2019, 30
  • [38] Adjuvant chemotherapy improves survival in high-risk stage II colon cancer: a retrospective cohort study
    Liu, Lin-Lin
    Xiang, Zuo-Lin
    THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2022, 15
  • [39] Interferon Alpha Adjuvant Therapy in Patients With High-Risk Melanoma: A Systematic Review and Meta-analysis
    Mocellin, Simone
    Pasquali, Sandro
    Rossi, Carlo R.
    Nitti, Donato
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2010, 102 (07): : 493 - 501
  • [40] Chronomodulated Capecitabine and Adjuvant Radiation in Intermediate-risk to High-risk Rectal Cancer A Phase II Study
    Bajetta, Emilio
    Pietrantonio, Filippo
    Buzzoni, Roberto
    Ferrario, Erminia
    Valvo, Francesca
    Mariani, Luigi
    Dotti, Katia F.
    Biondani, Pamela
    Formisano, Barbara
    Gevorgyan, Arpine
    Grassi, Paolo
    Di Bartolomeo, Maria
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2014, 37 (06): : 545 - 549
12345